Published in JAMA · View the paper (DOI)
A new study from Boston Medical Center found that injectable extended-release buprenorphine is limited by cost and treatment retention, while oral buprenorphine may be a more cost-effective option. The opioid overdose crisis requires a broad range of effective treatments, including injectable formulations.
Coverage from 2 institutions